Therapy Clinical Trials in Beijing, Beijing Municipality
54 recruitingBeijing, Beijing Municipality, China
Showing 1–20 of 54 trials
Recruiting
Phase 2
Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors
Lung CancerRadiotherapyImmune Checkpoint Inhibitor+1 more
Tianjin Medical University Cancer Institute and Hospital30 enrolled3 locationsNCT07058948
Recruiting
Phase 2
Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer
Neoadjuvant TherapyImmunotherapyTislelizumab+3 more
Seventh Medical Center of PLA General Hospital50 enrolled1 locationNCT07458529
Recruiting
To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)
Neoadjuvant TherapyLung NeoplasmsMinimal Residual Disease+1 more
Peking University People's Hospital100 enrolled1 locationNCT07291921
Recruiting
Phase 3
Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.
Whole-Brain Radiotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences134 enrolled1 locationNCT07443397
Recruiting
Not Applicable
MR-linac Guided Ultra-hypofractionated RT for Prostate Cancer (SMART-P01 and SMART-P02)
Radiotherapy Side EffectProstate CancerOligometastatic Disease+4 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences50 enrolled1 locationNCT05183074
Recruiting
Not Applicable
Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer
Colon CancerImmunotherapyMismatch Repair Deficiency
Peking Union Medical College Hospital18 enrolled2 locationsNCT06215677
Recruiting
Phase 2
Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT
SafetyLocally Advanced Non-Small Cell Lung CancerThoracic Radiotherapy
JIANYANG WANG44 enrolled1 locationNCT07037680
Recruiting
Not Applicable
Adjuvant Chemotherapy for High Malignant Prostate Cancer
Prostate CancerChemotherapyRadiation Therapy+1 more
Peking University First Hospital315 enrolled2 locationsNCT06864533
Recruiting
Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer
RadiotherapyLung Cancer (NSCLC)Neoadjuvant Immunotherapy+1 more
Peking University Cancer Hospital & Institute500 enrolled4 locationsNCT06926179
Recruiting
Not Applicable
Photoacoustic/Ultrasound Imaging for Breast Nodule Diagnosis, Molecular Classification, and Neoadjuvant Chemotherapy Response Evaluation
Breast CancerBreast MassesBreast Cancer Treated with Neoadjuvant Chemotherapy
Peking Union Medical College Hospital500 enrolled1 locationNCT06908291
Recruiting
Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma
Lung CancerAdvanced Hepatocellular CarcinomaOligometastasis+2 more
Sun Yat-sen University470 enrolled1 locationNCT06644430
Recruiting
Not Applicable
Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer
Colon CancerRectal CancerChemotherapy Effect+2 more
Peking Union Medical College Hospital200 enrolled1 locationNCT05424692
Recruiting
Phase 2
Sodium Glycididazole Reduces the Adverse Reactions of Concurrent Chemoradiotherapy
Chemoradiotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences40 enrolled1 locationNCT06667622
Recruiting
Not Applicable
Super-Hypofractionated Partial Breast Irradiation
Breast CancerRadiotherapy Side Effect
Cancer Institute and Hospital, Chinese Academy of Medical Sciences50 enrolled1 locationNCT06615466
Recruiting
Not Applicable
Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer
CDK4/6 InhibitorChemotherapeutic ToxicityTrastuzumab+5 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences148 enrolled1 locationNCT06197581
Recruiting
A Biomarker Exploratory Study of Dual Blockade of PD1/PDL1 and CTLA4 and Anti-angiogenic Therapy
MSS Metastatic Colorectal CancersMSI Solid Tumors Refractory to PD1/PDL1 Antibody Monotherapy
Peking University Cancer Hospital & Institute50 enrolled1 locationNCT06549907
Recruiting
I-125 Seeds Implantation in the Treatment of Recurrent Lung Cancer After Radiotherapy
Non-small Cell Lung CancerBrachytherapy
Peking University Third Hospital30 enrolled1 locationNCT04071418
Recruiting
Phase 2
Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer
HR+/HER2- Advanced Breast CancerTargeted Therapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences102 enrolled1 locationNCT05983107
Recruiting
Phase 2Phase 3
Optical Surface Monitoring Technology-Guided Large-Segment Radiotherapy for Breast Cancer
Breast CancerOptical Surface Monitoring TechnologyLarge-segment Radiotherapy
Peking Union Medical College Hospital556 enrolled1 locationNCT05804916
Recruiting
Not Applicable
Multi-points and Full-thickness Biopsy in the Diagnosis of cCR After Neoadjuvant Therapy for Rectal Cancer
Neoadjuvant TherapyMetastasisRectal Cancer+1 more
Beijing Chao Yang Hospital260 enrolled1 locationNCT04743102